Depomed Inc (NASDAQ:DEPO)

7.44
Delayed Data
As of Feb 16
 +0.28 / +3.91%
Today’s Change
4.31
Today|||52-Week Range
17.86
-7.58%
Year-to-Date
Opioid Litigants Get Boost From Senate Report
Feb 13 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close7.16
Today’s open7.17
Day’s range7.03 - 7.49
Volume2,159,345
Average volume (3 months)1,458,142
Market cap$468.8M
Data as of 4:00pm ET, 02/16/2018

Growth & Valuation

Earnings growth (last year)-15.08%
Earnings growth (this year)-43.04%
Earnings growth (next 5 years)+25.00%
Revenue growth (last year)+33.02%
P/E ratioNM
Price/Sales2.42
Price/Book1.84

Competitors

 Today’s
change
Today’s
% change
SVASinovac Biotech Ltd+0.01+0.12%
GLYCGlycoMimetics Inc-0.34-1.34%
AVEOAveo Pharmaceuticals...0.000.00%
ACIUAC Immune SA+0.32+2.81%
Data as of 4:00pm ET, 02/16/2018

Financials

Next reporting dateFebruary 20, 2018
EPS forecast (this quarter)$0.11
Annual revenue (last year)$455.9M
Annual profit (last year)-$88.7M
Net profit margin-19.46%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
Arthur Joseph Higgins
Chief Financial Officer &
Senior Vice President
August J. Moretti
Corporate headquarters
Newark, California

Forecasts